- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Patent holdings for IPC class A61P 9/02
Total number of patents in this class: 285
10-year publication summary
|
8
|
17
|
24
|
20
|
24
|
22
|
17
|
15
|
13
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Nevakar Injectables Inc. | 45 |
11 |
| La Jolla Pharma,llc | 14 |
8 |
| F. Hoffmann-La Roche AG | 7828 |
6 |
| Regeneron Pharmaceuticals, Inc. | 4591 |
5 |
| Genentech, Inc. | 4061 |
4 |
| Boehringer Ingelheim International GmbH | 4535 |
4 |
| Bayer Pharma AG | 1028 |
4 |
| Amgen Inc. | 4337 |
4 |
| Daiichi Sankyo Company, Limited | 1885 |
4 |
| The Trustees of Indiana University | 800 |
4 |
| Novartis AG | 10350 |
3 |
| Takeda Pharmaceutical Company Limited | 2719 |
3 |
| BIAL - Portela & CA, S.A. | 214 |
3 |
| Children's Medical Center Corporation | 1927 |
3 |
| Tersera Therapeutics LLC | 65 |
3 |
| Theravance Biopharma R&D IP, LLC | 427 |
3 |
| Talengen International Limited | 81 |
3 |
| Rainbow Engineering Services | 3 |
3 |
| Allergan, Inc. | 2220 |
2 |
| Massachusetts Institute of Technology | 10196 |
2 |
| Other owners | 203 |